Relmada Therapeutics IncNASDAQ:RLMD
- LAST PRICE3.4800
- TODAY'S CHANGE (%)0.2000 (6.0976%)
- Bid / Lots3.4000/ 1
- Ask / Lots3.5500/ 29
- Open / Previous Close3.3500 / 3.2800
- Day Range
- 52 Week Range
- Volume170,342
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RLMD |
|---|---|---|
| 09:32 ET | 963 | 3.35 |
| 09:34 ET | 2596 | 3.57 |
| 09:36 ET | 2842 | 3.55 |
| 09:38 ET | 3932 | 3.59 |
| 09:39 ET | 2379 | 3.54 |
| 09:43 ET | 400 | 3.5 |
| 09:50 ET | 285 | 3.525 |
| 09:59 ET | 200 | 3.48 |
| 10:06 ET | 600 | 3.49 |
| 10:08 ET | 314 | 3.48 |
| 10:10 ET | 5033 | 3.41 |
| 10:14 ET | 5100 | 3.437 |
| 10:15 ET | 500 | 3.5 |
| 10:21 ET | 746 | 3.47 |
| 10:24 ET | 1100 | 3.468 |
| 10:30 ET | 200 | 3.42 |
| 10:33 ET | 339 | 3.38 |
| 10:35 ET | 100 | 3.37 |
| 10:44 ET | 5614 | 3.33 |
| 10:46 ET | 100 | 3.35 |
| 11:09 ET | 500 | 3.375 |
| 11:13 ET | 200 | 3.3934 |
| 11:15 ET | 200 | 3.375 |
| 11:18 ET | 120 | 3.3786 |
| 11:20 ET | 100 | 3.3941 |
| 11:22 ET | 1889 | 3.375 |
| 11:33 ET | 2500 | 3.3904 |
| 11:40 ET | 17961 | 3.46 |
| 11:47 ET | 320 | 3.46 |
| 11:51 ET | 1100 | 3.475 |
| 12:03 ET | 100 | 3.49 |
| 12:05 ET | 5000 | 3.48 |
| 12:09 ET | 3139 | 3.465 |
| 12:12 ET | 451 | 3.4634 |
| 12:21 ET | 1100 | 3.475 |
| 12:23 ET | 9433 | 3.5 |
| 12:27 ET | 300 | 3.5 |
| 12:30 ET | 300 | 3.515 |
| 12:38 ET | 445 | 3.5 |
| 12:39 ET | 9600 | 3.48 |
| 12:45 ET | 150 | 3.495 |
| 12:52 ET | 1909 | 3.49 |
| 12:54 ET | 6237 | 3.47 |
| 01:01 ET | 100 | 3.465 |
| 01:03 ET | 500 | 3.4501 |
| 01:06 ET | 108 | 3.4584 |
| 01:10 ET | 500 | 3.465 |
| 01:17 ET | 800 | 3.47 |
| 01:19 ET | 1335 | 3.485 |
| 01:30 ET | 112 | 3.48 |
| 01:32 ET | 800 | 3.5 |
| 01:33 ET | 600 | 3.47 |
| 01:48 ET | 285 | 3.485 |
| 01:50 ET | 300 | 3.485 |
| 02:02 ET | 900 | 3.485 |
| 02:06 ET | 3000 | 3.47 |
| 02:26 ET | 231 | 3.46 |
| 02:40 ET | 1812 | 3.45 |
| 02:45 ET | 200 | 3.4623 |
| 02:47 ET | 200 | 3.42 |
| 02:49 ET | 5100 | 3.43 |
| 02:51 ET | 1000 | 3.4223 |
| 02:54 ET | 21601 | 3.465 |
| 03:09 ET | 100 | 3.45 |
| 03:23 ET | 200 | 3.45 |
| 03:27 ET | 150 | 3.4675 |
| 03:34 ET | 100 | 3.43 |
| 03:36 ET | 101 | 3.44 |
| 03:39 ET | 200 | 3.44 |
| 03:41 ET | 124 | 3.4502 |
| 03:43 ET | 478 | 3.45 |
| 03:45 ET | 2418 | 3.455 |
| 03:48 ET | 5600 | 3.45 |
| 03:52 ET | 2848 | 3.475 |
| 03:56 ET | 200 | 3.475 |
| 03:59 ET | 3941 | 3.48 |
Sep 17, 2024
DJ Relmada Therapeutics Raised to Buy From Hold by Jefferies, from 8:56AM ET on Tuesday Sep 17, 2024 by Dow Jones
8:56AM ET on Tuesday Sep 17, 2024 by Dow Jones
Sep 16, 2024
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm, from 9:36PM ET on Monday Sep 16, 2024 by Dow Jones
9:36PM ET on Monday Sep 16, 2024 by Dow Jones
Sep 5, 2024
Kuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law Firm, from 9:29AM ET on Thursday Sep 05, 2024 by Dow Jones
9:29AM ET on Thursday Sep 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Relmada Therapeutics Inc | 105.0M | -1.2x | --- |
X4 Pharmaceuticals Inc | 104.7M | 7.3x | --- |
Eledon Pharmaceuticals Inc | 103.9M | -1.0x | --- |
Bioatla Inc | 106.3M | -1.0x | --- |
Regulus Therapeutics Inc | 103.4M | -1.3x | --- |
Tiziana Life Sciences Ltd | 103.1M | -5.8x | --- |
Company Information
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
Contact Information
- Headquarters
- 2222 Ponce De Leon Blvd. 3Rd FloorCORAL GABLES, FL, United States 33134
- Phone
- 646-876-3459
- Fax
- ---
Executives
- Independent Chairman of the Board
- Charles Casamento
- Chief Executive Officer, Director
- Sergio Traversa
- Chief Financial Officer
- Maged Shenouda
- Chief Accounting, Compliance Officer
- Charles Ence
- Acting Chief Scientific Officer
- Paolo Manfredi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $105.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 30.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.42 |
EPS | $-2.88 |
Book Value | $2.84 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
